In the global research and development of anti-cancer drugs, antibody-drug conjugates (ADCs) have emerged as one of the most dynamic and high-profile focus areas.
The latest McKinsey report indicates that China is experiencing rapid growth in the field of next-generation innovative therapies, among which ADC drugs stand out prominently. Accounting for 54% of the global clinical pipeline, ADCs have become a core embodiment of China’s pharmaceutical innovation capacity.
Against this backdrop, the inaugural session of the Innovative Drug Salon Series, co-initiated by Kaisi Club and Xinglin Fanzhou (an alumni enterprise of the Shanghai Institute of Materia Medica), centers on "Challenges and Opportunities in ADC Drug R&D". The event aims to pool cross-industry expertise for in-depth discussions on pivotal topics spanning differentiated ADC project initiation, clinical development, and technological breakthroughs.
Shanghai Institute of Materia Medica, Chinese Academy of Sciences (Haike Road Campus)
501 Haike Road, Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, P.R.China
Huang Changjiang
TargetLink Biotech
Founder & Chief Scientist
Dr. Huang Changjiang is a top expert in ADC research and development with over a decade of experience in the field. He is the primary inventor of 15 granted patents and an additional 32 patent applications related to ADC technology. Dr. Huang has mentored numerous postdoctoral researchers specializing in ADC development and created the popular course Hot Topics and Frontiers in Life Science Research. He has provided technical consulting services to many well-known biopharmaceutical enterprises at home and abroad, participated in the evaluation of national and provincial research programs, and taken part in core talent cultivation initiatives.
Dr. Huang has received prestigious honors including Distinguished Taishan Scholar and Industrial Leading Talent. Projects led by him were funded by major national special research grants under the 12th and 13th Five-Year Plans, alongside tens of millions of RMB in new drug development funds. He oversaw and participated in the early-stage molecular design, R&D and preparation of multiple ADC candidates, including RC48 — China’s first marketed targeted ADC therapeutic, which launched successfully in June 2021. The product has delivered remarkable clinical benefits, substantially prolonging survival and improving quality of life for patients with malignant tumors.
Prior to his domestic career, Dr. Huang completed his postdoctoral fellowship in Molecular Medicine at the David Geffen School of Medicine, University of California, Los Angeles (UCLA), where he spent 18 years conducting fundamental research in medical molecular biology. During this period, he authored more than 100 publications, monographs and patents, laying a robust molecular biology foundation for innovative new drug discovery.
After returning to China in 2012, Dr. Huang held successive senior R&D leadership roles: Vice President of R&D at Yantai RemeGen Co., Ltd., Chief Scientific Officer at Mabwell (International) Biopharmaceutical Co., Ltd., and Chief Scientific Officer of Shanghai TargetKang LianYao Biotech Co., Ltd. starting in 2024.
Dr. Huang has supported his employers in building state-of-the-art ADC technology platforms from scratch. He spearheaded the development of groundbreaking ADC therapeutics that broke key technical bottlenecks in antibody-drug conjugation, enabling rapid product commercialization and international expansion. He personally led multiple antibody clone optimization programs covering conjugate process design, physicochemical characterization, and scaled-up conjugation manufacturing workflows. Furthermore, he built high-performance R&D teams and core technical platforms. Drawing on his profound expertise in linker design, conjugation chemistry, and small-molecule toxin synthesis, he has advanced multiple novel ADC candidates into clinical trials. These accomplishments have cemented his employers’ competitive edge in biopharmaceuticals and delivered landmark contributions to the broader ADC industry.
Chen Guangliang
Attending Physician, Department of Medical Oncology, Fudan University Shanghai Cancer Center
MD, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany
Member, Medical Oncology Subgroup, Head and Neck Cancer Committee, Shanghai Anti-Cancer Association
Has published 30 academic papers as first/corresponding author in international medical journals.
Youth Editorial Board Member of Aging & Disease, Med Research and The Innovation Oncology.
Principal Investigator of 2 National Natural Science Foundation of China projects; holds 1 granted patent.
Research Focus: Clinical and translational research of head and neck malignancies.
Wei Shi
Head of PCC Screening Platform, Tangling Biology
Associate Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Dr. Wei Shi earned his Bachelor’s degree from West China School of Pharmacy, Sichuan University in 2016 and his Doctor of Science degree from the Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2021, under the supervision of Researcher Wei Huang. He completed his postdoctoral research at the Shanghai Institute of Materia Medica from 2021 to 2023.
His research focuses on the development of antibody conjugation technologies and ADC therapeutics. He has published numerous SCI research papers in peer-reviewed journals including Angewandte Chemie International Edition, Nature Communications, Journal of Medicinal Chemistry, and Acta Pharmaceutica Sinica B. He has filed more than 10 patents and received funding support from multiple national and provincial research programs.
Liu Yaqing
Deputy General Manager
Shanghai Pudong Wuxin Insurance Broker Co., Ltd.
With over ten years of professional experience in the clinical research sector, Liu leads his team to deliver service and administration for more than 3,000 clinical trial insurance projects, covering innovative drugs, cell therapies, gene therapies, Class III medical devices, and various Investigator-Initiated Trials (IITs). In 2015, he participated in a Phase I new drug clinical trial as a research subject.
He has co-authored two documents: Guangdong Consensus on Handling Injuries to Subjects in Drug Clinical Trials (2020 Edition) and Reflections and Recommendations Arising from the Review of Funding Agreements for Investigator-Initiated Clinical Research.
Social Part-time Appointment: Youth Committee Member, Medical Ethics Special Committee, Beijing Chronic Disease Prevention and Health Education Research Association.
Adhering to the principles of rationality and legality, he has settled more than 400 compensation claims, including communication and negotiation for all types of complex indemnity cases. His work has effectively eased doctor-subject conflicts, safeguarded sound clinical research operations, and fostered the healthy and orderly development of clinical research.
Xie Hui
Senior Director of Clinical Research, Desigen Therapeutics
Dr. Xie holds an MD from The Chinese University of Hong Kong, and serves as a research fellow and attending physician. He is a recipient of the Shanghai Pujiang Talent Program and a consulting expert of the Chinese Academy of Engineering.
With two decades of dedicated experience in innovative pharmaceutical R&D and translational research, he has presided over and participated in two National Natural Science Foundation projects, acted as a core technical backbone for two Major National Science and Technology Projects for New Drug Creation during the 13th Five-Year Plan period, and led one Natural Science Project funded by the Shanghai Science and Technology Commission.
He claimed the National First Prize in the Biomedicine Category of the China Innovation and Entrepreneurship Competition twice:
- 2016: World’s first artificial retina project
- 2019: Class 1.1 anti-tumor new drug project
- Dr. Xie has spearheaded more than 10 Phase I and Phase II early clinical trials of innovative therapeutics, covering small molecules, mono- and bispecific antibodies, ADCs and other modalities. He has advanced two self-developed innovative drugs to best-in-class status globally and supported the launch of China’s first XPO1 inhibitor.
- He has published numerous research articles in SCI journals including PNAS, Nature Neuroscience, IEEE Transactions on Neural Systems and Rehabilitation Engineering, and Signal Transduction and Targeted Therapy.
He serves as Associate Editor of Frontiers in Oncology and Distinguished Reviewer for the Institute of Physics Publishing (IOPP), UK. His professional memberships include the Chinese Society of Clinical Oncology (CSCO), American Society of Clinical Oncology (ASCO), and Institute of Electrical and Electronics Engineers (IEEE).
Registration Methods
- Scan the QR code below to sign up.
Special Notes
This activity is free of charge, but registration is subject to review. Please submit authentic and valid information to pass the review.
Registration closes at 12:00 on December 4. If places are fully occupied in advance, registration will be closed early. Late applications will not be accepted. Thank you for your understanding.
Registration Methods
- Scan the QR code below to sign up.
Contact
Contact Person: Zhu Zhu
Phone / WeChat: 17621371081
Email: zhuhl@hiheit.com
